Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemBuMel for Poor-Risk Myeloma
NCT01237951Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2010
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine in multiple myeloma (MM), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoint: Stringent Complete Remission at 100 days. Started Nov 2010; status: completed.
02
Drugs
gemcitabine
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01237951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01237951.